Switch theme
Sign up to access all valuation multiples
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
2000
501
LTM Revenue $161M
LTM EBITDA -$13.5M
-$17.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OraSure has a last 12-month revenue (LTM) of $161M and a last 12-month EBITDA of -$13.5M.
In the most recent fiscal year, OraSure achieved revenue of $186M and an EBITDA of -$13.6M.
OraSure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OraSure valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | XXX | $186M | XXX | XXX | XXX |
| Gross Profit | $70.4M | XXX | $79.4M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | -$13.5M | XXX | -$13.6M | XXX | XXX | XXX |
| EBITDA Margin | -8% | XXX | -7% | XXX | XXX | XXX |
| EBIT | -$25.2M | XXX | -$23.9M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -13% | XXX | XXX | XXX |
| Net Profit | -$33.8M | XXX | -$19.5M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OraSure's stock price is $3.
OraSure has current market cap of $215M, and EV of -$17.9M.
See OraSure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$17.9M | $215M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OraSure has market cap of $215M and EV of -$17.9M.
OraSure's trades at -0.1x EV/Revenue multiple, and 1.3x EV/EBITDA.
Equity research analysts estimate OraSure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OraSure has a P/E ratio of -6.4x.
See valuation multiples for OraSure and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $215M | XXX | $215M | XXX | XXX | XXX |
| EV (current) | -$17.9M | XXX | -$17.9M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBIT | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/Gross Profit | -0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.4x | XXX | -11.0x | XXX | XXX | XXX |
| EV/FCF | -3.2x | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOraSure's last 12 month revenue growth is -20%
OraSure's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
OraSure's rule of 40 is -4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OraSure's rule of X is -57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OraSure and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -20% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -8% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 108% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4% | XXX | -27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OraSure acquired XXX companies to date.
Last acquisition by OraSure was XXXXXXXX, XXXXX XXXXX XXXXXX . OraSure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OraSure founded? | OraSure was founded in 2000. |
| Where is OraSure headquartered? | OraSure is headquartered in United States of America. |
| How many employees does OraSure have? | As of today, OraSure has 501 employees. |
| Who is the CEO of OraSure? | OraSure's CEO is Ms. Carrie Eglinton Manner. |
| Is OraSure publicy listed? | Yes, OraSure is a public company listed on NAS. |
| What is the stock symbol of OraSure? | OraSure trades under OSUR ticker. |
| When did OraSure go public? | OraSure went public in 1992. |
| Who are competitors of OraSure? | Similar companies to OraSure include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of OraSure? | OraSure's current market cap is $215M |
| What is the current revenue of OraSure? | OraSure's last 12 months revenue is $161M. |
| What is the current revenue growth of OraSure? | OraSure revenue growth (NTM/LTM) is -20%. |
| What is the current EV/Revenue multiple of OraSure? | Current revenue multiple of OraSure is -0.1x. |
| Is OraSure profitable? | Yes, OraSure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OraSure? | OraSure's last 12 months EBITDA is -$13.5M. |
| What is OraSure's EBITDA margin? | OraSure's last 12 months EBITDA margin is -8%. |
| What is the current EV/EBITDA multiple of OraSure? | Current EBITDA multiple of OraSure is 1.3x. |
| What is the current FCF of OraSure? | OraSure's last 12 months FCF is $5.6M. |
| What is OraSure's FCF margin? | OraSure's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of OraSure? | Current FCF multiple of OraSure is -3.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
